Kaleido Biosciences, Inc. (KLDO)

NASDAQ: KLDO · IEX Real-Time Price · USD
2.23
0.13 (6.19%)
At close: Jan 25, 2022 4:00 PM
2.35
0.12 (5.38%)
After-hours:Jan 25, 2022 7:38 PM EST
Market Cap94.99M
Revenue (ttm)855,000
Net Income (ttm)-90.03M
Shares Out42.59M
EPS (ttm)-2.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume54,230
Open2.10
Previous Close2.10
Day's Range2.06 - 2.32
52-Week Range1.90 - 20.50
Beta-0.39
AnalystsBuy
Price Target14.80 (+563.7%)
Earnings Daten/a

About KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. It a...

IndustryPharmaceuticals
IPO DateFeb 28, 2019
Employees82
Stock ExchangeNASDAQ
Ticker SymbolKLDO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 14.80, which is an increase of 563.68% from the latest price.

Price Target
$14.80
(563.68% upside)
Analyst Consensus: Buy

News

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...

4 days ago - GlobeNewsWire

Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?

Kaleido Biosciences, Inc. (KLDO) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

2 weeks ago - Zacks Investment Research

Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Th...

LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...

1 month ago - GlobeNewsWire

Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer

LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...

2 months ago - GlobeNewsWire

Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now

Kaleido Biosciences, Inc. (KLDO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

2 months ago - Zacks Investment Research

Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 1.82% and -58.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

2 months ago - Zacks Investment Research

Kaleido Biosciences Reports Third Quarter 2021 Financial Results

--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease...

2 months ago - GlobeNewsWire

Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround

Kaleido Biosciences, Inc. (KLDO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn...

2 months ago - Zacks Investment Research

Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...

3 months ago - GlobeNewsWire

Why Did Kaleido Shares Plunge 10% On Tuesday?

Kaleido Biosciences Inc (NASDAQ: KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in mild-to-moderate ulcerative colitis (UC...

3 months ago - Benzinga

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols:ABUSADVMMNKDTRVN
3 months ago - PennyStocks

Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, ...

Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented

3 months ago - GlobeNewsWire

FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial

The FDA has issued a warning letter to Kaleido Biosciences Inc (NASDAQ: KLDO), blasting its “failure to submit Investigational New Drug applications for a clinical trial with an investigational new drug...

4 months ago - Benzinga

Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference

LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...

4 months ago - GlobeNewsWire

Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Kaleido Biosciences Reports Second Quarter 2021 Financial Results

--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the de...

5 months ago - GlobeNewsWire

Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical...

On track to initiate Phase 2 trial in the first quarter of 2022 On track to initiate Phase 2 trial in the first quarter of 2022

5 months ago - GlobeNewsWire

Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors

Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors

5 months ago - GlobeNewsWire

Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference

LEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

5 months ago - GlobeNewsWire

Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...

7 months ago - GlobeNewsWire

Kaleido Biosciences Reports First Quarter 2021 Financial Results

--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-...

8 months ago - GlobeNewsWire

Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic ...

LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to tr...

9 months ago - GlobeNewsWire

Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit

LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbi...

9 months ago - GlobeNewsWire